



Nanomaterials for Cancer Photothermal Therapy

Guest Editor:

Dr. Duarte De Melo-Diogo

CICS-UBI – Centro de
Investigação em Ciências da
Saúde, Universidade da Beira
Interior, Avenida Infante D.
Henrique, 6200-506 Covilhã,
Portugal

Deadline for manuscript
submissions:

closed (10 November 2021)

Message from the Guest Editor

Dear Colleagues,

Nanomaterials with specific properties can reach the tumor site and produce, upon interaction with laser radiation, a temperature increase that can damage cancer cells. For this purpose, NIR light is generally used due to its minimal interaction with biological components, ensuring a high tissue penetration depth and reduced off-target heating. Hence, nanomaterials with a high NIR absorption have been extensively investigated for cancer photothermal therapy. On the other hand, the assembly of nanostructures with NIR-absorbing materials has also been explored. The nanomaterials' photoinduced heat can also trigger other events like release of encapsulated agents, opening a venue for combining nanomaterials' mediated photothermal therapy with other therapeutic modalities.

This Special Issue focuses on nanomaterials aimed for cancer photothermal therapy. Research articles covering the synthesis/formulation of novel NIR-light-responsive nanomaterials, their functionalization and characterization, as well as their application in cancer combination therapy are welcome. Comprehensive reviews are also welcomed.

Dr. Duarte De Melo-Diogo

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of
Pharmacy, Rutgers, The State
University of New Jersey, William
Levine Hall, Room 225C, 160
Frelinghuysen Road, Piscataway,
NJ 08854-8020, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma